Intellectus Partners LLC Buys 12,333 Shares of Zoetis Inc. $ZTS

Intellectus Partners LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 138.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,264 shares of the company’s stock after buying an additional 12,333 shares during the period. Intellectus Partners LLC’s holdings in Zoetis were worth $2,675,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. RFG Advisory LLC grew its position in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after acquiring an additional 80 shares during the period. YANKCOM Partnership lifted its holdings in shares of Zoetis by 3.5% during the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after acquiring an additional 81 shares during the period. Beese Fulmer Investment Management Inc. boosted its stake in shares of Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its stake in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. grew its holdings in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ZTS. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. UBS Group dropped their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Bank of America boosted their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. Finally, Stifel Nicolaus decreased their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday, May 22nd. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus price target of $133.92.

Insider Buying and Selling

In other news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 11,650 shares of company stock worth $886,384 in the last quarter. Insiders own 0.22% of the company’s stock.

Zoetis Stock Up 1.5%

Shares of NYSE ZTS opened at $77.51 on Thursday. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $171.52. The firm’s 50-day simple moving average is $101.99 and its 200 day simple moving average is $116.09. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market cap of $32.49 billion, a price-to-earnings ratio of 12.85, a price-to-earnings-growth ratio of 1.25 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the previous year, the business posted $1.48 EPS. The company’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts expect that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Some market commentary says Zoetis could still be a value opportunity, with one analysis describing the stock as a potential deep-value play with significant upside if the business stabilizes.
• Neutral Sentiment: Zoetis presented at the William Blair Growth Stock Conference, but no major new operating update from that event was highlighted in the headlines provided.
• Negative Sentiment: Multiple law firms announced or reminded investors about a class-action lawsuit alleging securities-law violations during the Jan. 14, 2025 to May 6, 2026 period, with several notices urging shareholders to seek lead-plaintiff status by July 27, 2026. These repeated legal alerts can weigh on the stock. Article Title
• Negative Sentiment: One article said Zoetis has underperformed its industry peers over the past year, reinforcing concerns about recent relative stock performance.
• Negative Sentiment: Investor notices from Robbins Geller, Levi & Korsinsky, the Schall Law Firm, Howard G. Smith, Bernstein Liebhard, The Gross Law Firm, DJS Law Group, and others all highlighted the ongoing lawsuit, increasing headline risk for ZTS.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.